- Home
- SORA vs ABOS Comparison
SORA vs ABOS Comparison
Compare SORA & ABOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.93
N/A
Current Price
$2.69
Company Overview
Basic Information| Metric | SORA | ABOS |
|---|---|---|
| Founded | 2001 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.0M | 155.7M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SORA | ABOS |
|---|---|---|
| Price | $1.93 | $2.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 358.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.57 | $0.86 |
| 52 Week High | $10.27 | $3.05 |
Technical Indicators
Market Signals| Indicator | SORA | ABOS |
|---|---|---|
| Relative Strength Index (RSI) | 39.81 | 55.93 |
| Support Level | $1.57 | $1.17 |
| Resistance Level | $3.08 | $3.05 |
| Average True Range (ATR) | 0.20 | 0.21 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 30.67 | 67.09 |
Price Performance
Historical Comparison SORA
ABOS
About SORA Top Win International Limited Ordinary Shares
AsiaStrategy is a wholesaler engaged in trading, distribution, and retail of luxury watches of international brands. The Group sources its luxury watches from Europe, Singapore, Japan, and Hong Kong, then sells the goods to retail sellers and other distributors in the watch industry.
About ABOS Acumen Pharmaceuticals Inc.
Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.